Navigation Links
Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
Date:2/7/2013

ssion ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:

Joshua Drumm , PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Z Trim Holdings, Inc. Records First Non-GMO Corn Sales
2. ARAMARK Introduces Worlds First Reusable Validated Sterile Goggle That Remains Clear When Irradiated
3. First-to-Market Online Identity Theft Protection - Allweb Technologies Launches AllWebID
4. Origin Agritech Limited Reports Unaudited First Quarter Financial Results For Three Months Ended December 31, 2012
5. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
6. Pathway BioLogic is Chosen by Easy Gardener to Formulate the U.S.’s First Microbial Enhanced Natural Water Soluble Plant Food
7. First bedside DNA test to be introduced in Czech Republic
8. Waters Unveils Industrys First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 2013
9. Carolina Conceptions Announces the Delivery of their First Egg Freeze Pregnancy
10. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
11. First Point-of-Care DNA Test Submitted for FDA Clearance by Spartan Bioscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier this ... L. Sherley, director of the Adult Stem Cell Technology Center, ... and under appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the essence ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 4, 2011 Advanced Life Sciences Holdings, Inc. ... biopharmaceutical company engaged in the discovery, development and commercialization ... oncology and respiratory diseases, today announced that it will ... held January 10-12th in San Francisco. ...
... 2011 Neogen Corporation (Nasdaq: NEOG ) announced ... FY 2011, which ended Nov. 30, increased 33% from the ... to $6,110,000, or $0.26 per share, compared to the prior ... $43,931,000, compared to the prior year,s $35,251,000. Year-to-date revenues for ...
... Inc. announced today that it has received clearance from ... to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ... solid tumors. (Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO ) ... the activity of semaphorin 4D (SEMA4D).  It is the ...
Cached Biology Technology:Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference 2Neogen Reports 33% Increase in Net Income 2Neogen Reports 33% Increase in Net Income 3Neogen Reports 33% Increase in Net Income 4Neogen Reports 33% Increase in Net Income 5Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced ... Home Button Synaptics Fingerprint Sensor Technology Analysis" report ... Based on a totally different sensing ... first time a fingerprint sensor in its product. ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" report ... One major trend upcoming in this ... biomedical applications. Chemical sensors help in recording of patient ...
(Date:12/11/2014)... Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... addition of the "Biometrics Market in India 2015-2019" ... major trend emerging in this market is the adoption ... than one characteristic of an individual for verification and ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... is a newly discovered life history among the 28,300 species ... from arid southwestern Madagascar spends up to three-quarters of its ... is a mere 4 to 5 months. No other known ... a short life span. The new research is reported in ...
... Mary Estes of Baylor College of Medicine and her ... toxic protein that affects the intestines, causing diarrhea. ... receptor on intestinal cells through which the enterotoxin interacts ... the receptor might not be straightforward," said the professor ...
... factors associated with Crohn,s disease have been discovered, ... about the disease. An international consortium of Crohn,s ... Canadian researchers Dr. John D. Rioux from ... Drs. Mark Silverberg and Hillary Steinhart from Mount ...
Cached Biology News:Unheard of life history for a vertebrate 2Integrins as receptors give insight into rotavirus and diarrhea 2Montreal Heart Institute and Mount Sinai Hospital researchers contribute to Crohn's disease study 2
Incomplete Adjuvant...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: